Hydrogel corneal inlay improves near, intermediate, distance vision at 3 months

Print 17 February 2014
Matt Hasson / Healio Ophthalmology

A hydrogel corneal inlay improved near, intermediate and distance vision, regardless of preoperative refractive error, according to a study presented at Hawaiian Eye 2014.

Roger F. Steinert, MD, OSN Cornea/External Disease Board Member, spoke about the Raindrop near vision inlay (ReVision Optics).

“This is really better than anybody expected,” Steinert said. “It’s providing uninterrupted functional vision and satisfaction across a very wide range of preop refractive errors. … We think the real sweet spot is going to be somewhere around the very low hyperopic side and not higher than +1.5 D.”

Roger F. Steinert

The study included 188 patients with a mean age of 51 years and mean preoperative manifest refraction between –0.5 D and +1.5 D.

Mean postoperative monocular uncorrected near visual acuity exceeded 20/25 and approached 20/20 in all eyes at 3 months. Near visual acuity was unaffected by age and preoperative refractive error, Steinert said.

Mean monocular uncorrected intermediate visual acuity exceeded 20/25 in all eyes.

Mean monocular uncorrected distance visual acuity decreased slightly in eyes with manifest refraction of –0.5 D to +0.5 D but improved in eyes with manifest refraction of +0.75 D to +1.5 D. Distance visual acuity was 20/25 or better in eyes with preoperative refraction of +0.25 D to +1.5 D.

Mean patient satisfaction was four on a scale of five, Steinert said. 

Disclosure: Steinert is medical monitor in U.S. Food and Drug Administration clinical trials for ReVision Optics.

Sourse

Return

All Partners

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news